Manufacturers are reporting shortages of a common medication for sexually transmitted disease (STDs); rates of cancers related to human papillomavirus (HPV) increased from 2007 to 2016; early trial data show patients infected with coronavirus disease 2019 (COVID-19) respond to remdesivir.
After President Trump promoted a commonly prescribed antibiotic for sexually transmitted diseases (STDs) as a potential cure for coronavirus disease 2019 (COVID-19), suppliers of azithromycin tablets (Z-Packs) have been struggling to meet the demand, The Hill reports. The FDA loosened restrictions on how the drug can be used and as a result, some doctors are combining azithromycin with hydroxychloriquine—an anti-malarial medication—to treat patients with COVID-19. However, azithromycin is currently the only approved treatment for chlamydia in pregnant women; there is little evidence that the 2-drug combination is effective against the virus, although trials are underway.
According to a new CDC report, rates of oral and pharynx cancers increased from around 35,000 cases in 2007 to nearly 45,000 cases in 2016. The increase was driven by high rates of human papillomavirus (HPV)-associated cancers, researchers said. In particular, tonsil and oropharynx cancers caused by HPV increased by more than 2% per year. In comparison, non-HPV-associated cancer rates decreased by around 0.4% each year. Researchers note public health efforts focused on HPV vaccination will be essential to prevent future increases.
An early report of partial, incomplete data of Gilead’s remdesivir shows it could be an effective treatment for patients with COVID-19, according to Reuters. A University of Chicago hospital participating in the clinical trial said it is seeing rapid symptom recoveries, with the majority of patients being discharged in less than a week after receiving treatment. Complete results from the phase 3 study will become available at the end of the month, and researchers emphasize partial data should not be used to draw conclusions. In addition, there is no control group and the patient sample size is small.
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
2 Commerce Drive
Cranbury, NJ 08512